Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 267831, 11 pages
http://dx.doi.org/10.1155/2015/267831
Review Article

The Role of Mifepristone in Meningiomas Management: A Systematic Review of the Literature

1Service of Neurosurgery, Department of Clinical Neuroscience, Faculty of Human Medicine and Biology, University Hospital of Lausanne, 46 rue du Bugnon, 1011 Lausanne, Switzerland
2Department of Neurosurgery, University Hospital of Bicetre, Faculty of Medicine of Paris Sud, 78 rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France

Received 26 February 2015; Accepted 27 April 2015

Academic Editor: Maria Caffo

Copyright © 2015 Giulia Cossu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Q. T. Ostrom, H. Gittleman, P. Liao et al., “CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011,” Neuro-Oncology, vol. 16, supplement 4, pp. iv1–iv63, 2014. View at Publisher · View at Google Scholar
  2. D. Simpson, “The recurrence of intracranial meningiomas after surgical treatment,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 20, no. 1, pp. 22–39, 1957. View at Publisher · View at Google Scholar · View at Scopus
  3. B. S. Schoenberg, B. W. Christine, and J. P. Whisnant, “Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer,” Neurology, vol. 25, no. 8, pp. 705–712, 1975. View at Publisher · View at Google Scholar · View at Scopus
  4. E. R. Bickerstaff, J. M. Small, and I. A. Guest, “The relapsing course of certain meningiomas in relation to pregnancy and menstruation,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 21, no. 2, pp. 89–91, 1958. View at Publisher · View at Google Scholar
  5. R. D. Weyand, C. C. Mac, and R. B. Wilson, “The effect of pregnancy on intracranial meningiomas occurring about the optic chiasm,” The Surgical Clinics of North America, vol. 31, no. 4, pp. 1225–1233, 1951. View at Google Scholar · View at Scopus
  6. M. S. Donnell, G. A. Meyer, and W. L. Donegan, “Estrogen-receptor protein in intracranial meningiomas,” Journal of Neurosurgery, vol. 50, no. 4, pp. 499–502, 1979. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Blankenstein, G. Blaauw, S. W. J. Lamberts, and E. Mulder, “Presence of progesterone receptors and absence of oestrogen receptors in human intracranial meningioma cytosols,” European Journal of Cancer & Clinical Oncology, vol. 19, no. 3, pp. 365–370, 1983. View at Publisher · View at Google Scholar · View at Scopus
  8. M. A. Blankenstein, C. van der Meulen-Dijk, and J. H. H. Thijssen, “Assay of oestrogen and progestin receptors in human meningioma cytosols using immunological methods,” Clinica Chimica Acta, vol. 165, no. 2-3, pp. 189–195, 1987. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Bozzetti, R. Camisa, R. Nizzoli et al., “Estrogen and progesterone receptors in human meningiomas: biochemical and immunocytochemical evaluation,” Surgical Neurology, vol. 43, no. 3, pp. 230–234, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. W. L. McGuire, K. B. Horwitz, O. H. Pearson, and A. Segaloff, “Current status of estrogen and progesterone receptors in breast cancer,” Cancer, vol. 39, no. 6, pp. 2934–2947, 1977. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Poisson, H. Magdelenat, P. M. Martin, and et al, “Progestin receptors in human normal leptomeninges in adults,” Revue Neurologique, vol. 140, no. 1, pp. 14–19, 1984. View at Google Scholar · View at Scopus
  12. E.-E. Baulieu, “Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor,” Science, vol. 245, no. 4924, pp. 1351–1357, 1989. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Fjelldal, B. T. Moe, A. Ørbo, and G. Sager, “MCF-7 cell apoptosis and cell cycle arrest: non-genomic effects of progesterone and mifepristone (RU-486),” Anticancer Research, vol. 30, no. 12, pp. 4835–4840, 2010. View at Google Scholar · View at Scopus
  14. C. R. Tieszen, A. A. Goyeneche, B. N. Brandhagen, C. T. Ortbahn, and C. M. Telleria, “Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression,” BMC Cancer, vol. 11, article 207, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. F. El Etreby, Y. Liang, and R. W. Lewis, “Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture,” The Prostate, vol. 43, no. 1, pp. 31–42, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. M.-F. Lin, M. H. Kawachi, M. R. Stallcup, S. M. Grunberg, and F.-F. Lin, “Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone,” The Prostate, vol. 26, no. 4, pp. 194–204, 1995. View at Publisher · View at Google Scholar · View at Scopus
  17. A. A. Goyeneche, R. W. Carón, and C. M. Telleria, “Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo,” Clinical Cancer Research, vol. 13, no. 11, pp. 3370–3379, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. D.-Q. Li, Z.-B. Wang, J. Bai et al., “Reversal of multidrug resistance in drug-resistant human gastric cancer cell line SGC7901/VCR by antiprogestin drug mifepristone,” World Journal of Gastroenterology, vol. 10, no. 12, pp. 1722–1725, 2004. View at Google Scholar · View at Scopus
  19. Q.-L. Sun, X.-G. Zhang, Q.-T. Xing et al., “A study of mifepristone/IFN-γ-induced apoptosis of human cholangiocarcinoma cell line FRH-0201 in vitro,” OncoTargets and Therapy, vol. 5, pp. 335–342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. Navo, J. A. Smith, A. Gaikwad, T. Burke, J. Brown, and L. M. Ramondetta, “In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines,” Cancer Chemotherapy and Pharmacology, vol. 62, no. 3, pp. 483–489, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Jurado, A. Lopez-Flores, A. Alvarez, and P. García-López, “Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study,” Oncology Reports, vol. 22, no. 5, pp. 1237–1245, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. J. J. Olson, D. W. Beck, J. Schlechte, and P.-M. Loh, “Hormonal manipulation of meningiomas in vitro,” Journal of Neurosurgery, vol. 65, no. 1, pp. 99–107, 1986. View at Publisher · View at Google Scholar · View at Scopus
  23. M. A. Blankenstein, C. van der Meulen-Dijk, and J. H. H. Thijssen, “Effect of steroids and antisteroids on human meningioma cells in primary culture,” Journal of Steroid Biochemistry, vol. 34, no. 1–6, pp. 419–421, 1989. View at Publisher · View at Google Scholar · View at Scopus
  24. J. W. Koper, J. A. Foekens, R. Braakman, and S. W. J. Lamberts, “Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells,” Cancer Research, vol. 50, no. 9, pp. 2604–2607, 1990. View at Google Scholar · View at Scopus
  25. U. M. H. Schrell, E. F. Adams, R. Fahlbusch et al., “Hormone dependency of meningiomas,” The Lancet, vol. 333, no. 8651, pp. 1381–1382, 1989. View at Publisher · View at Google Scholar
  26. A. Wilisch-Neumann, D. Pachow, M. Wallesch et al., “Re-evaluation of cytostatic therapies for meningiomas in vitro,” Journal of Cancer Research and Clinical Oncology, vol. 140, no. 8, pp. 1343–1352, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Matsuda, K. Kawamoto, K. Kiya, K. Kurisu, K. Sugiyama, and T. Uozumi, “Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo,” Journal of Neurosurgery, vol. 80, no. 3, pp. 527–534, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. J. J. Olson, D. W. Beck, J. A. Schlechte, and P.-M. Loh, “Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice,” Journal of Neurosurgery, vol. 66, no. 4, pp. 584–587, 1987. View at Publisher · View at Google Scholar · View at Scopus
  29. S. M. Grunberg, M. H. Weiss, I. M. Spitz et al., “Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone,” Journal of Neurosurgery, vol. 74, no. 6, pp. 861–866, 1991. View at Publisher · View at Google Scholar · View at Scopus
  30. S. M. Grunberg, M. H. Weiss, C. A. Russell et al., “Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma,” Cancer Investigation, vol. 24, no. 8, pp. 727–733, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. S. W. J. Lamberts, H. L. J. Tanghe, C. J. J. Avezaat et al., “Mifepristone (RU 486) treatment of meningiomas,” Journal of Neurology Neurosurgery and Psychiatry, vol. 55, no. 6, pp. 486–490, 1992. View at Publisher · View at Google Scholar · View at Scopus
  32. R. J. W. de Keizer and J. W. A. Smit, “Mifepristone treatment in patients with surgically incurable sphenoid-ridge meningioma: a long-term follow-up,” Eye, vol. 18, no. 9, pp. 954–958, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Touat, G. Lombardi, P. Farina, M. Kalamarides, and M. Sanson, “Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486),” Acta Neurochirurgica, vol. 156, no. 10, pp. 1831–1835, 2014. View at Publisher · View at Google Scholar
  34. I. M. Spitz, S. M. Grunberg, N. Chabbert-Buffet, T. Lindenberg, H. Gelber, and R. Sitruk-Ware, “Management of patients receiving long-term treatment with mifepristone,” Fertility and Sterility, vol. 84, no. 6, pp. 1719–1726, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. S. M. Grunberg, C. Rankin, J. Townsend, J. Ahmadi, L. Feun, and R. Fredericks, Eds., Phase III Double-Blind Randomized Placebo-Controlled Study on Mifepristone (RU) for the Treatment of Unresectable Meningioma, American Society of Clinical Oncology, Alexandria, Va, USA, 2001.
  36. L. K. Nieman, T. M. Choate, G. P. Chrousos et al., “The progesterone antagonist RU 486. A potential new contraceptive agent,” The New England Journal of Medicine, vol. 316, no. 4, pp. 187–191, 1987. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Couzinet, N. Le Strat, A. Ulmann, E. E. Baulieu, and G. Schaison, “Termination of early pregnancy by the progesterone antagonist RU 486 (Mifepristone),” The New England Journal of Medicine, vol. 315, no. 25, pp. 1565–1570, 1986. View at Publisher · View at Google Scholar · View at Scopus
  38. O. Heikinheimoab, S. Ranta, S. Grunberg, and I. M. Spitz, “Alterations in sex steroids and gonadotropins in post-menopausal women subsequent to long-term mifepristone administration,” Steroids, vol. 65, no. 10-11, pp. 831–836, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. A. A. Murphy, A. J. Morales, L. M. Kettel, and S. S. C. Yen, “Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect,” Fertility and Sterility, vol. 64, no. 1, pp. 187–190, 1995. View at Google Scholar · View at Scopus
  40. S. H. Eisinger, S. Meldrum, K. Fiscella, H. D. le Roux, and D. S. Guzick, “Low-dose mifepristone for uterine leiomyomata,” Obstetrics and Gynecology, vol. 101, no. 2, pp. 243–250, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. N. C. A. Roelvink, W. Kamphorst, H. A. M. van Alphen, and B. R. Rao, “Pregnancy-related primary brain and spinal tumors,” Archives of Neurology, vol. 44, no. 2, pp. 209–215, 1987. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Sitruk-Ware and I. M. Spitz, “Pharmacological properties of mifepristone: toxicology and safety in animal and human studies,” Contraception, vol. 68, no. 6, pp. 409–420, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. J. W. Goodwin, J. Crowley, H. J. Eyre, B. Stafford, K. A. Jaeckle, and J. J. Townsend, “A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study,” Journal of Neuro-Oncology, vol. 15, no. 1, pp. 75–77, 1993. View at Publisher · View at Google Scholar · View at Scopus
  44. S. M. Grunberg and M. H. Weiss, “Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma,” Journal of Neuro-Oncology, vol. 8, no. 1, pp. 61–65, 1990. View at Google Scholar · View at Scopus
  45. J. Jääskeläinen, E. Laasonen, J. Kärkkäinen, M. Haltia, and H. Troupp, “Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA)—a pilot study of five cases,” Acta Neurochirurgica, vol. 80, no. 1-2, pp. 35–41, 1986. View at Publisher · View at Google Scholar · View at Scopus
  46. J. R. Jay, D. T. MacLaughlin, K. R. Riley, and R. L. Martuza, “Modulation of meningioma cell growth by sex steroid hormones in vitro,” Journal of Neurosurgery, vol. 62, no. 5, pp. 757–762, 1985. View at Publisher · View at Google Scholar · View at Scopus
  47. E. R. Waelti and T.-M. Markwalder, “Endocrine manipulation of meningiomas with medroxyprogesterone acetate: effect of MPA on growth of primary meningioma cells in monolayer tissue culture,” Surgical Neurology, vol. 31, no. 2, pp. 96–100, 1989. View at Publisher · View at Google Scholar · View at Scopus
  48. T.-M. Markwalder, H. A. Gerber, E. Waelti, T. Schaffner, and R. V. Markwalder, “Hormonotherapy of meningiomas with medroxyprogesterone acetate. Immunohistochemical demonstration of the effect of medroxyprogesterone acetate on growth fractions of meningioma cells using the monoclonal antibody Ki-67,” Surgical Neurology, vol. 30, no. 2, pp. 97–101, 1988. View at Publisher · View at Google Scholar · View at Scopus
  49. P. A. Martineau and M. Levental, “Large endometrial polyp in a patient on long-term mifepristone therapy,” Journal of Ultrasound in Medicine, vol. 19, no. 7, pp. 487–489, 2000. View at Google Scholar · View at Scopus
  50. H. R. Haak, R. J. W. de Keizer, J. C. W. Hagenouw-Taal, A. P. van Seters, G. J. Vielvoye, and H. van Dulken, “Successful mifepristone treatment of recurrent, inoperable meningioma,” The Lancet, vol. 336, no. 8707, pp. 124–125, 1990. View at Google Scholar · View at Scopus
  51. S. W. J. Lamberts, J. W. Koper, and F. H. de Jong, “The endocrine effects of long-term treatment with mifepristone (RU 486),” The Journal of Clinical Endocrinology & Metabolism, vol. 73, no. 1, pp. 187–191, 1991. View at Publisher · View at Google Scholar · View at Scopus
  52. O. Heikinheimo, S. Ranta, S. Grunberg, P. Lähteenmäki, and I. M. Spitz, “Alterations in the pituitary-thyroid and pituitary-adrenal axes—consequences of long-term mifepristone treatment,” Metabolism: Clinical and Experimental, vol. 46, no. 3, pp. 292–296, 1997. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Takiyama, H. Tanaka, Y. Takiyama, and I. Makino, “The effects of hydrocortisone and RU486 (mifepristone) on iodide uptake in porcine thyroid cells in primary culture,” Endocrinology, vol. 135, no. 5, pp. 1972–1979, 1994. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Rubello, N. Sonino, D. Casara, M. E. Girelli, B. Busnardo, and M. Boscaro, “Acute and chronic effects of high glucocorticoid levels on hypothalamic-pituitary-thyroid axis in man,” Journal of Endocrinological Investigation, vol. 15, no. 6, pp. 437–441, 1992. View at Publisher · View at Google Scholar · View at Scopus
  55. S. M. Grunberg, “Role of antiprogestational therapy for meningiomas,” Human Reproduction, vol. 9, supplement 1, pp. 202–207, 1994. View at Google Scholar · View at Scopus
  56. K.-P. Lesch, W. Schott, H.-G. Engl, S. Groß, and P. Thierauf, “Gonadal steroid receptors in meningiomas,” Journal of Neurology, vol. 234, no. 5, pp. 328–333, 1987. View at Publisher · View at Google Scholar · View at Scopus
  57. D. W. Hsu, J. T. Efird, and E. T. Hedley-Whyte, “Progesterone and estrogen receptors in meningiomas: prognostic considerations,” Journal of Neurosurgery, vol. 86, no. 1, pp. 113–120, 1997. View at Publisher · View at Google Scholar · View at Scopus
  58. D. S. Baxter, A. Orrego, J. V. Rosenfeld, and T. Mathiesen, “An audit of immunohistochemical marker patterns in meningioma,” Journal of Clinical Neuroscience, vol. 21, no. 3, pp. 421–426, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Huang, R. Buhl, H. H. Hugo, and H. M. Mehdorn, “Clinical and histological features of multiple meningiomas compared with solitary meningiomas,” Neurological Research, vol. 27, no. 3, pp. 324–332, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Kastner, A. Krust, B. Turcotte et al., “Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B,” The EMBO Journal, vol. 9, no. 5, pp. 1603–1614, 1990. View at Google Scholar · View at Scopus
  61. J. K. Richer, B. M. Jacobsen, N. G. Manning, M. G. Abel, D. M. Wolf, and K. B. Horwitz, “Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells,” The Journal of Biological Chemistry, vol. 277, no. 7, pp. 5209–5218, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. B. M. Jacobsen, J. K. Richer, S. A. Schittone, and K. B. Horwitz, “New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation,” The Journal of Biological Chemistry, vol. 277, no. 31, pp. 27793–27800, 2002. View at Publisher · View at Google Scholar · View at Scopus
  63. L. A. Helguero, M. Viegas, A. Asaithamby, G. Shyamala, C. Lanari, and A. A. Molinolo, “Progesterone receptor expression in medroxyprogesterone acetate-induced murine mammary carcinomas and response to endocrine treatment,” Breast Cancer Research and Treatment, vol. 79, no. 3, pp. 379–390, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. V. Wargon, L. A. Helguero, J. Bolado et al., “Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas,” Breast Cancer Research and Treatment, vol. 116, no. 3, pp. 449–460, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Sequeira, S. I. Vanzulli, P. Rojas et al., “The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer,” Oncotarget, vol. 5, no. 10, pp. 3246–3260, 2014. View at Google Scholar
  66. J. Chen, J. Wang, J. Shao et al., “The unique pharmacological characteristics of mifepristone (RU486): from terminating pregnancy to preventing cancer metastasis,” Medicinal Research Reviews, vol. 34, no. 5, pp. 979–1000, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. X. Cui, Z. W. Lazard, P. Zhang, T. A. Hopp, and A. V. Lee, “Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2,” Oncogene, vol. 22, no. 44, pp. 6937–6941, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. D.-Q. Li, Z.-B. Wang, J. Bai et al., “Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro,” World Journal of Gastroenterology, vol. 10, no. 18, pp. 2628–2631, 2004. View at Google Scholar · View at Scopus
  69. A. D. Norden, J. J. Raizer, L. E. Abrey et al., “Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma,” Journal of Neuro-Oncology, vol. 96, no. 2, pp. 211–217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Y. Wen, E. Quant, J. Drappatz, R. Beroukhim, and A. D. Norden, “Medical therapies for meningiomas,” Journal of Neuro-Oncology, vol. 99, no. 3, pp. 365–378, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. N. Andrae, E. Kirches, R. Hartig et al., “Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells,” European Journal of Cancer, vol. 48, no. 12, pp. 1831–1841, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. M. J. A. Puchner, V. H. Hans, A. Harati, F. Lohmann, M. Glas, and U. Herrlinger, “Bevacizumab-induced regression of anaplastic meningioma,” Annals of Oncology, vol. 21, no. 12, pp. 2445–2446, 2010. View at Publisher · View at Google Scholar · View at Scopus